RNAi agents and compositions for inhibiting expression of Asialoglycoprotein receptor 1

1. An RNAi agent for inhibiting expression of an ASGR1 gene, wherein the antisense strand consists of, consists essentially of, or comprises the nucleotide sequence (5′→3′):

(SEQ ID NO: 6)

AGCGACUUCAUCUUUCUUCCG;

or

(SEQ ID NO: 8)

AGCGACUUCAUCUUUCUUCGU;

and

a sense strand comprising a nucleotide sequence that is at least partially complementary to the antisense strand, wherein at least one nucleotide of the sense strand or the antisense strand is a modified nucleotide or wherein the RNAi agent comprises at least one modified internucleoside linkage.

2. The RNAi agent of claim 1 , wherein the sense strand consists of, consists essentially of, or comprises a nucleotide sequence that differs by 0 or 1 nucleotides from one of the following nucleotide sequences (5′→3′):

(SEQ ID NO: 15)

CGGAAGAAAGAUGAAGUCICU;

(SEQ ID NO: 16)

ACGAAGAAAGAUGAAGUCICU;

(SEQ ID NO: 17)

ACGAAGAAAGAUGAAGUCGCU;

(SEQ ID NO: 31)

CGGAAGAAAGAUGAAIUCICU;

or

(SEQ ID NO: 33)

CGGAAGAAAGAUGAAGUCGCU;

wherein I represents an inosine nucleotide.

3. The RNAi agent of claim 1 , wherein 0, 1, 2, 3, or 4 nucleotides of the RNAi agent are ribonucleotides (2′-hydroxyl nucleotides).

4. The RNAi agent of claim 3 , wherein the sense strand further includes inverted abasic residues at the 3′ terminal end of the nucleotide sequence, at the 5′ end of the nucleotide sequence, or at both the 3′ and 5′ terminal ends.

5. The RNAi agent of claim 1 , wherein the antisense strand comprises, consists of, or consists essentially of the modified nucleotide sequence (5′→3′):

(SEQ ID NO: 5)

asGfscGfaCfuucauCfuUfuCfuUfcsCfsg;

(SEQ ID NO: 7)

asGfscGfaCfuucauCfuUfuCfuUfcsGfsu;

(SEQ ID NO: 9)

asGfscsgacuucauCfuUfuCfuUfcGfsu;

or

wherein a represents 2′-O-methyl adenosine, c represents 2′-O-methyl cytidine, g represents 2′-O-methyl guanosine, and u represents 2′-O-methyl uridine; Af represents 2′-fluoro adenosine, Cf represents 2′-fluoro cytidine, Gf represents 2′-fluoro guanosine, and Uf represents 2′-fluoro uridine; s represents a phosphorothioate linkage; and wherein 0, 1, or 2 nucleotides of the sense strand are ribonucleotides (2′-hydroxyl nucleotides).

6. The RNAi agent of claim 5 , wherein the sense strand comprises, consists of, or consists essentially of a modified nucleotide sequence that differs by 0 or 1 nucleotides from one of the following nucleotide sequences (5′→3′):

(SEQ ID NO: 23)

cggaagaaAfGfAfugaagucicu;

(SEQ ID NO: 24)

acgaagaaAfGfAfugaagucicu;

(SEQ ID NO: 25)

acgaagaaAfGfAfugaagucgcu;

(SEQ ID NO: 32)

cggaagaaAfGfAfugaaiucicu;

or

(SEQ ID NO: 34)

cggaagaaAfGfAfugaagucgcu;

wherein a represents 2′-O-methyl adenosine, c represents 2′-O-methyl cytidine, g represents 2′-O-methyl guanosine, i represents 2′-O-methyl inosine, and u represents 2′-O-methyl uridine; and Af represents 2′-fluoro adenosine, Cf represents 2′-fluoro cytidine, Gf represents 2′-fluoro guanosine, and Uf represents 2′-fluoro uridine.

7. The RNAi agent of claim 1 , wherein the sense strand and antisense strand for a duplex pair that comprises, consists of, or consists essentially of a modified nucleotide sequence that differs by 0 or 1 nucleotides from one of the following nucleotide sequence pairs (5′→3′):

(SEQ ID NO: 5)

asGfscGfaCfuucauCfuUfuCfuUfcsCfsg

and

(SEQ ID NO: 23)

cggaagaaAfGfAfugaagucicu;

(SEQ ID NO: 7)

asGfscGfaCfuucauCfuUfuCfuUfcsGfsu

and

(SEQ ID NO: 24)

acgaagaaAfGfAfugaagucicu;

(SEQ ID NO: 9)

asGfscsgacuucauCfuUfuCfuUfcGfsu

and

(SEQ ID NO: 25)

acgaagaaAfGfAfugaagucgcu;

(SEQ ID NO: 5)

asGfscGfaCfuucauCfuUfuCfuUfcsCfsg

and

(SEQ ID NO: 32)

cggaagaaAfGfAfugaaiucicu;

or

(SEQ ID NO: 5)

asGfscGfaCfuucauCfuUfuCfuUfcsCfsg

and

(SEQ ID NO: 34)

cggaagaaAfGfAfugaagucgcu,

wherein a represents 2′-O-methyl adenosine, c represents 2′-O-methyl cytidine, g represents 2′-O-methyl guanosine, i represents 2′-O-methyl inosine, and u represents 2′-O-methyl uridine, and Af represents 2′-fluoro adenosine, Cf represents 2′-fluoro cytidine, Gf represents 2′-fluoro guanosine, and Uf represents 2′-fluoro uridine.

8. The RNAi agent of claim 5 , wherein the RNAi agent is conjugated to a targeting ligand at the 5′ end of the sense strand.

9. The RNAi agent of claim 8 , wherein the targeting ligand is a tridentate ligand that includes N-acetyl-galactosamine and has the structure selected from the group consisting of:

10. A composition comprising the RNAi agent of claim 1 and a pharmaceutically acceptable excipient.

11. A method for inhibiting expression of an ASGR1 gene in a cell, the method comprising administering to the cell the RNAi agent of claim 1 .

12. The method of claim 11 , wherein the cell is within a human subject.

13. A method for inhibiting expression of an ASGR1 gene in a subject, the method comprising administering to the subject the composition of claim 10 .

14. A method of treating an ASGR1-related disease or disorder, the method comprising administering to a subject in need thereof an effective amount of the composition of claim 10 .

15. The method of claim 14 , wherein the ASGR1-related disease or disorder is obesity, metabolic syndrome, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, abnormal lipid and/or cholesterol metabolism, atherosclerosis, diabetes, cardiovascular disease, coronary artery disease, myocardial infarction, peripheral vascular disease, or cerebrovascular disease.

16. A method for reducing non-HDL cholesterol in a subject in need thereof, the method comprising administering to the subject an effective amount of the composition of claim 10 .

17. The method of claim 16 , wherein the non-HDL cholesterol is LDL cholesterol.

18. A method for reducing the risk of myocardial infarction in a subject in need thereof, the method comprising administering to the subject an effective amount of the composition of claim 10 .

19. The method of claim 18 , wherein the subject is diagnosed with coronary artery disease.

20. The method of claim 18 , wherein the subject has elevated levels of non-HDL cholesterol.

21. The method of claim 11 , wherein the RNAi agent is administered at a dose of about 0.05 mg/kg to about 5.0 mg/kg of body weight of the human subject.